?Invivyd (IVVD) Reports Strong Q4 Growth, Advances COVID Antibody to Phase 3 [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
fourth-quarter 2025 net product revenue of $17.2 million from PEMGARDA (pemivibart), representing 25% growth year over year and a 31% increase from the prior quarter. The company ended 2025 with $226.7 million in cash and equivalents, strengthened by financing completed in the second half of the year. With a current ratio of 2.47, Invivyd enters 2026 with solid liquidity to support operations and pipeline advancement. Invivyd has launched its DECLARATION Phase 3 pivotal trial for VYD2311, a monoclonal antibody designed as an alternative to vaccination for COVID-19 prevention. The program received FDA Fast Track designation in December 2025. The triple-blind, randomized study will enroll approximately 1,770 participants, with top-line results expected by mid-2026. Management pointed to continued demand for antibody-based prevention as vaccination rates decline, while PEMGARDA's 93.3% gross margin highlights the product's commercial potential. The company is also broadening its pipe
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Adimab Records Another Year of Double-Digit Clinical Program Growth [Yahoo! Finance]Yahoo! Finance
- Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target [Yahoo! Finance]Yahoo! Finance
- Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business HighlightsGlobeNewswire
- BTIG Initiates Invivyd (IVVD) Coverage, Cites VYD2311's Superior Market Potential Over Pemgarda [Yahoo! Finance]Yahoo! Finance
- Does Invivyd's (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? [Yahoo! Finance]Yahoo! Finance
IVVD
Earnings
- 11/6/25 - Miss
IVVD
Sec Filings
- 1/8/26 - Form 8-K
- 12/29/25 - Form SCHEDULE
- 12/29/25 - Form EFFECT
- IVVD's page on the SEC website